Hemoglobin A1c Testing Devices Market Report 2025

The hemoglobin a1c testing devices market size has grown rapidly in recent years. It will grow from $1.88 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to holistic diabetes management programs, continuous innovation, improvement in healthcare infrastructure, preventive healthcare practices, home healthcare trends.

The hemoglobin a1c testing devices market size is expected to see rapid growth in the next few years. It will grow to $3.24 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to point-of-care testing expansion, home testing and self-monitoring, focus on preventive healthcare, increasing aging population, healthcare accessibility expansion. Major trends in the forecast period include continuous innovation and cost efficiency, rising diabetes prevalence, shift towards point-of-care testing, technological advancements, home healthcare and self-monitoring.

The increasing prevalence of diabetes is anticipated to drive the growth of the hemoglobin A1C testing devices market. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels. Hemoglobin A1C testing provides crucial information regarding average blood glucose levels in individuals, aiding in the diagnosis of type 2 diabetes, pre-diabetes, and diabetes management. This enables individuals to monitor their condition and make informed treatment decisions to prevent complications. For instance, in 2022, the Centers for Disease Control and Prevention, a U.S.-based national public health agency, reported that approximately 37.3 million people, or 11.3% of the U.S. population, were affected by diabetes. Consequently, the rising number of diabetes patients will fuel the growth of the hemoglobin A1C testing devices market.

The easy accessibility of point-of-care (POC) tests is expected to boost the hemoglobin A1C testing devices market. Point-of-care testing (POCT) refers to testing conducted at the site where the patient receives medical care. With improved access to POC tests, healthcare providers can enhance patient satisfaction by reducing long wait times for test results. Portable hemoglobin A1C testing devices can deliver quick and accurate results in various settings, including doctors' offices, pharmacies, and even homes. For example, according to the standards set by the World Health Organization (WHO), POC diagnostics are user-friendly and readily accessible, suitable for use not only by laboratory personnel but also by other healthcare professionals with basic training in POC testing. Therefore, the increased accessibility of point-of-care (POC) tests will contribute to the growth of the hemoglobin A1C testing devices market.

Major companies in the hemoglobin A1C testing devices market are concentrating on developing innovative solutions, including at-home HbA1c test kits, to give patients greater control over their diabetes management. An at-home HbA1c test kit is a medical device that allows individuals to measure their hemoglobin A1c (HbA1c) levels conveniently at home. For example, in May 2022, OmegaQuant, LLC, a U.S.-based independent CLIA-certified laboratory, launched an innovative HbA1c test that enables users to monitor their blood sugar levels from home. This at-home testing kit allows individuals to collect a blood sample with a simple finger stick, providing insights into their average blood glucose levels over the past three months. The results indicate optimal ranges for healthy blood sugar management, empowering users to make informed dietary and lifestyle decisions.

Key companies in the hemoglobin A1C testing devices market are focusing on the integration of microfluidic immunofluorescence tests for hemoglobin A1C to enhance their market position. Microfluidic immunofluorescence (MIF) is a sophisticated technique that merges the principles of microfluidics and immunofluorescence to detect and quantify various biomarkers in biological samples. For instance, in May 2022, LumiraDx Limited, a London-based next-generation point-of-care diagnostics company, announced that its HbA1c test had received CE Marking. When utilized with the LumiraDx Platform, this test delivers results from a sample application in under seven minutes, allowing for rapid monitoring of diabetic patients and quick screening and identification of individuals at risk of developing the disease.

In October 2023, Abbott Laboratories, a U.S.-based medical device company, entered into a partnership with WW International. This collaboration integrates Abbott's FreeStyle Libre continuous glucose monitoring technology with WeightWatchers' diabetes-focused weight management program, offering real-time glucose insights and personalized nutritional guidance to help individuals with diabetes make informed dietary choices and improve both weight management and glycemic control. WW International, Inc. is a U.S.-based company that provides services for weight loss and maintenance, fitness, and mindset, including the comprehensive Weight Watchers diet program.

Major companies operating in the hemoglobin A1c testing devices market include Arkray Inc, Abbott Laboratories, Polymer Technology Systems Inc, Bio-Rad Laboratories Inc, Menarini Group, F Hoffmann-La Roche AG, Siemens Healthineers AG, Tosoh Corporation, Trinity Biotech plc, Transasia Bio-Medicals Limited, Beckman Coulter Inc, Diazyme Laboratories Inc, EKF Diagnostics Holdings plc, HemoCue AB, OSANG Healthcare Co Ltd, Danaher, Bayer AG, Thermo Fisher Scientific Inc., PTS Diagnostics India Private Limited, Nova Biomedical, Randox Laboratories Ltd., ACON Laboratories Inc., DiaSys Diagnostic Systems GmbH, Erba Mannheim, Green Cross Medical Science Corp., Infopia Co. Ltd., TaiDoc Technology Corporation, Werfen, Zhejiang Orient Gene Biotech Co. Ltd.

North America was the largest region in the hemoglobin A1c testing devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hemoglobin A1c testing devices market during the forecast period. The regions covered in the hemoglobin a1c testing devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemoglobin a1c testing devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hemoglobin A1c testing device serves as the analytical tool utilized in quantifying HbA1C. In this process, glucose binds to hemoglobin, forming glycated hemoglobin within an individual's blood sample. Its purpose is to monitor blood sugar levels consistently, contributing to efficient and effective diabetic management.

Two primary types of hemoglobin A1c testing devices exist, benchtop devices and handheld devices. Benchtop devices are designed for convenient usage on a laboratory workbench. Employed in laboratories to assess blood sugar levels in patients, benchtop hemoglobin A1c testing devices make use of various technologies such as ion exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay, and others. These technologies find application in hospitals, pharmaceuticals, medical devices, and laboratory testing.

The hemoglobin a1c testing devices market research report is one of a series of new reports that provides hemoglobin a1c testing devices market statistics, including hemoglobin a1c testing devices industry global market size, regional shares, competitors with a hemoglobin a1c testing devices market share, detailed hemoglobin a1c testing devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobin a1c testing devices industry. This hemoglobin a1c testing devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemoglobin A1c testing device market consists of sales of automated, semi-automated, and bio-sensor-based hemoglobin A1c testing devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.